SERUM LIPOPROTEIN(a) LEVEL IN SUBJECTS FREE OF CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS-RELATED DISEASES: THE RELATIONSHIP WITH LIPID AND GLUCOSE METABOLISM PARAMETERS AND ARTERIAL STIFFNESS

Aim of the study – in subjects without any signs of atherosclerosis to study the associations between blood serum level of lipoprotein(a) (Lp(a)) from one hand, and lipoprotein profile, insulinmediated glucose utilization parameters and pulse wave velocity (PWV), from the other.

Material and methods. Totally 202 subjects (68 men, 134 women) aged 25–75 years without clinical manifestations of atherosclerosis-related diseases but with cardiovascular disease risk factors were included into the study. Blood lipid and carbohydrate parameters were measured by standard methods, serum concentration of Lp(a), apolipoproteins (apo) AI, AII, and B – immunoturbidimetrically. PWV was used as a measure of arterial stiffness.

Results. Serum level of Lp(a) positively correlated with apo B concentration (R=0,143; p=0,043) and negatively with apo АII content (R=–0,286; p<0,0001). No associations between Lp(a) level and glucose metabolism parameters were found. At the same time, the comparison in groups differed by Lp(a) level according to the highest quintile of its distribution, showed that in subjects with elevated Lp(a) (≥ 50 mg/dl), PWV, apo AII concentration, and postprandial glycemia were lower, while apo B concentration and apo B/apo AI ratio were higher, than in those with Lp(a) < 50 mg/dl. Subjects with high Lp(a) level have upward trend to increased frequency of atherosclerotic plaques presence in carotid arteries.

Conclusions. The relationship between elevated Lp(a) level with the initial stages of atherosclerosis was found; however, this association wasn’t coupled with increased arterial stiffness. Higher Lp(a) level positively correlated with apo B concentration and negatively with apo AII content. The relationship between Lp(a) and glucose level was observed only after glucose load in glucose tolerance test and might be explained by more favorable glycemic control in subjects with increased Lp(a) level. 

1. Nordestgaard B.G., Chapman M.J., Ray K., Bore ´n J., Andreotti F., Watts G.F., Ginsberg H., Amarenco P., Catapano A., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik P., Masana L., Reiner Z., Taskinen M.R., Tokgo ¨zoglu L., Tybjærg-Hansen A., European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status // Eur. Heart J. 2010. Vol. 31, N 23. P. 2844–2853.

2. Тмоян Н.А., Афанасьева О.И., Ежов М.В. Роль липопротеида(а) в развитии атеросклеротического поражения периферических и сонных артерий // Кардиология. 2018. Т. 58, N 6. С. 70–78.

3. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies // Circulation. 2000. Vol. 102, N 10. P. 1082– 1085.

4. Афанасьева О.И., Уткина Е.А., Артемьева Н.В., Ежов М.В., Адамова И.Ю., Покровский С.Н. Повышенная концентрация липопротеида(а) и наличие мелких плотных подфракций атерогенных липопротеидов как независимые факторы риска развития ишемической болезни сердца // Кардиология. 2016. Т. 56, N 6. С. 5–11.

5. Sorokin A., Kotani K. Lipoprotein (a) and arterial stiffness parameters // Puls (Basel). 2015. Vol. 3, N 2. P. 148–152.

6. Дислипидемия и атеросклероз / ред. Р.Г. Оганов. М.: ГОЭТАР-Медиа, 2009.

7. Кругликова А.С., Стражеско И.Д., Ткачева О.Н., Акашева Д.У., Плохова Е.В., Пыхтина В.С., Дудинская Е.Н., Исайкина О.Ю., Шарашкина Н.В., Озерова И.Н., Выгодин В.А., Гомыранова Н.В. Взаимосвязь факторов сердечно-сосудистого риска и биологии теломер с признаками сосудистого старения // Кардиоваскуляр. терапия и профилактика. 2014. Т. 13, N 3. С. 11–17.

8. Liao J., Farmer J. Arterial stiffness as a risk factor for coronary artery disease // Curr. Atheroscler. Rep. 2014. Vol. 16, N 2. P. 387.

9. Гомыранова Н.В., Метельская В.А., Ткачева О.Н., Озерова И.Н., Перова Н.В., Стражеско И.Д. Биохимические маркеры атерогенных нарушений в системе липопротеинов: связь с биологическим и хронологическим старением сосудов // Атеросклероз и дислипидемии. 2014. N 4. С. 14–19.

10. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling // Diabetes Care. 2004. Vol. 27, N 6. P. 1487–1495.

11. Gutt M., Davis C.L., Spitzer S.B., Llabre M.M., Kumar M., Czarnecki E.M., Schneiderman N., Skyler J.S., Marks J.B. Validation of the insulin sensitivity index (ISI0,120): comparison with other measures // Diab. Res. Clin. Pract. 2000. Vol. 47, N 3. P. 177– 184.

12. Sharma M., von Zychlinski-Kleffmann A., Porteous C.M., Jones G.T., Williams M.J., McCormick S.P. Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids // J. Lipid Res. 2015. Vol. 56, N 7. P. 1318– 1328.

13. Бутина Е.К., Бочкарева Е.В. Значение субклинического атеросклероза сонных артерий для первичной профилактики сердечно-сосудистых заболеваний. Обзор основных международных исследований // Рац. фармакотерапия в кардиологии. 2016. Т. 12, N 5. С. 558–566.

14. Parish S., Peto R., Palmer A., Clarke R., Lewington S., Offer A., Whitlock G., Clark S., Youngman L., Sleight P., Collins R., International Studies of Infarct Survival Collaborators. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls // Eur. Heart J. 2009. Vol. 30, N 17. P. 2137–2146.

15. Vlachopoulos C. Progress towards identifying biomarkers of vascular aging for total cardiovascular risk prediction // J. Hypertens. 2012. Vol. 30. P. S19–S26.

16. Wakabayashi I., Masuda H. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus // Clin. Chim. Acta. 2006. Vol. 373, N 1-2. P. 127–131.

17. Chan D.C., Ng T.W., Watts G.F. Apolipoprotein A-II: evaluating its significance in dislipidaemia, insulin resistance, and atherosclerosis // Ann. Med. 2012. Vol. 44, N 4. P. 313–324.

18. Melchior J.T., Street S.E., Andraski A.B., Furtado J.D., Sacks F.M., Shute R.L., Greve E.I., Swertfeger D.K., Li H., Shah A.S., Lu L.J., Davidson W.S. Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1 // J. Lipid Res. 2017. Vol. 58, N 7. P. 1374– 1385.

19. Kido T., Kurata H., Kondo K., Itakura H., Okazaki M., Urata T., Yokoyama S. Bioinformatic analysis of plasma apolipoproteins A-I and A-II revealed unique features of A-I/A-II HDL particles in human plasma // Sci. Rep. 2016. Vol. 16, N 6. P. 31532.

20. Gao X., Yuan S., Jayaraman S., Gursky O. Differential stability of high-density lipoprotein subclasses: effects of particle size and protein composition // J. Mol. Biol. 2009. Vol. 387, N 3. P. 628–638.

21. Gordon S.M., Davidson W.S., Urbina E.M., Dolan L.M., Heink A., Zang H., Lu L.J., Shah A.S. The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth // Diabetes. 2013. Vol. 62, N 8. P. 2958–2967.

22. Pamir N., Hutchins P.M., Ronsein G.E., Wei H., Tang C., Das R., Vaisar T., Plow E., Schuster V., Reardon C.A., Weinberg R., Dichek D.A., Marcovina S., Getz G.S., Heinecke J.W., Koschinsky M.L. Plasminogen promotes cholesterol efflux by the ABCA1 pathway // JCI Insight. 2017. Vol. 2, N 15. ID e92176.

23. Birjmohun R.S., Dallinga-Thie G.M., Kuivenhoven J.A., Stroes E.S.G., Otvos J.D., Wareham N.J., Luben R., Kastelein J.J.P., Khaw K.T., Boekholdt S.M. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease // Circulation. 2007. Vol. 116, N 18. P. 2029–2035.

24. Winkler K., Hoffmann M.M., Seelhorst U., Wellnitz B., Boehm B.O., Winkelmann B.R., Ma ¨rz W., Scharnagl H. Apolipoprotein A-II is a negative risk indicator for cardiovascular and total mortality: findings from the Ludwigshafen Risk and Cardiovascular Health Study // Clin. Chem. 2008. Vol. 54, N 8. P. 1405–1406.

25. Александрович О.В., Озерова И.Н., Олферьев А.М., Сердюк А.П., Метельская В.А., Перова Н.В. Ассоциация уровня аполипопротеина А-II сыворотки крови с комбинированной гиперлипидемией и нарушенной толерантностью к глюкозе // Бюл. эксперим. биологии и медицины. 2006. Т. 141, N 6. С. 625–628.

26. Arakaki N., Ueno A., Oribe T., Takeda Y., Takao T., Shimonishi Y., Hara S. Insulin-stimulating protein from human plasma. Chemical characteristics and biological activity // Eur. J. Biochem. 1986. Vol. 161, N 2. P. 491–504.

27. Ding L., Song A., Dai M., Xu M., Sun W., Xu B., Sun J., Wang T., Xu Y., Lu J., Wang W., Bi Y., Ning G. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population // J. Lipid Res. 2015. Vol. 56, N 4. P. 920–926.

28. Mu-Han-Ha-Li D.L., Zhai T.Y., Ling Y., Gao X. LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk // J. Lipid Res. 2018. Vol. 59, N 5. P. 884–891.

29. Rainwater D.L., Haffner S.T. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype // Arterioscler. Thromb. Vasc. Biol. 1998. Vol. 18, N 8. P. 1335–1341.

30. Qureshi K., Clements R.H., Saeed F., Abrams G.A. Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic fatty liver disease // J. Obes. 2010. ID 741521.